PMGC Holdings Inc.
ELAB
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.4M
$3.45
▼ -2.68%
P/E
—
Mkt Cap
$2.4M
52-Wk Range
$3.40–$2,671
52-Week Range
$3.40 - $2,671.20
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 99.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- First-in-class engineered probiotic technology for muscle preservation
- Proprietary approach addressing unmet needs in GLP-1 combination therapy
- Focused pipeline in high-growth obesity and aesthetic medicine markets
- Scientific research and development expertise in biopharmaceutical innovation
Bear Case
1 risk
- Low volatility (beta -0.3).
Growth
No forward estimates available
Expanding GLP-1 receptor agonist market and increasing patient adoption
Value
Valuation data unavailable
Momentum
Falling
-72.3% over 3m
Quality
Thin
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying ELAB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
AUG 14, 2026
Most recent quarter reported revenue of $1.3M. Reported EPS of $0.00. Gross margin 29.5%.
Reported EPS · last 4Q
0 of 1 beats
Q3 26
—
Revenue trend · last 8Q
—
—
-100%
-100%
-46%
+117%
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$527.5K
-$1.7M
$0
$0
$285.9K
$304.1K
$682.0K
$1.3M
Margins · last 8Q
Gross
29.5%
Operating
—
Profit
0.0%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How ELAB stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related